MTOR and lymphoma: Knowledge of the implications of mTOR in carcinogenesis comes essentially from evidence obtained from familial cancer syndromes that develop as a consequence of mutations of negative regulators of mTOR, such as TSC1-TSC2 and PTEN [133], as well as from experimental studies in mouse models of lymphoma involving alterations of eIF4E [134].